Illumina Files Definitive Proxy Materials and Sends Letter to Stockholders
SAN DIEGO– Illumina, Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, announced today that it filed definitive proxy materials with the Securities and Exchange Commission (SEC) in connection with its 2012 Annual Meeting of Stockholders, to be held on April 18, 2012.
Illumina’s Board of Directors has also sent a letter urging stockholders to protect the value of their investment by rejecting Roche’s unsolicited and opportunistic efforts to acquire Illumina on grossly inadequate terms.
The Board recommends that stockholders vote for the election of Illumina’s highly qualified nominees on the WHITE proxy card.

